SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCOctober 18, 2026

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

Firmonertinib, a once-daily oral EGFR tyrosine kinase inhibitor, produced confirmed objective responses in 68% of patients at 240 mg and 43% at 160 mg when given first line for metastatic non-small cell lung cancer (NSCLC) carrying EGFR P-loop and αC-helix compressing (PACC) mutations. Xiuning Le and colleagues reported the phase 1b FURTHER study, together with preclinical work on the drug, in Cancer Cell.
Share

In brief

  • In the phase 1b FURTHER study (NCT05364073), first-line firmonertinib produced confirmed objective responses in 43% of patients at 160 mg (n=25) and 68% at 240 mg (n=22) with metastatic EGFR PACC-mutant NSCLC.
  • Median progression-free survival was 11.1 months at 160 mg and 16.0 months at 240 mg.
  • Median duration of response was not reached at 160 mg and was 14.6 months at 240 mg.
  • Among patients with brain metastases at baseline, the intracranial objective response rate was 47% (8/17).
  • Treatment-related adverse events led to dose reductions in 19% and 24% of patients and to discontinuation in 3% and 0%, at 160 mg and 240 mg respectively.

Study at a glance

  • Study: FURTHER, phase 1b (NCT05364073)
  • Population: Metastatic EGFR PACC-mutant NSCLC, first line
  • Treatment: Firmonertinib 160 mg (n=25) or 240 mg (n=22), randomised
  • Objective response rate: 43% (160 mg) and 68% (240 mg), confirmed
  • Median duration of response: Not reached (160 mg) and 14.6 months (240 mg)
  • Median progression-free survival: 11.1 months (160 mg) and 16.0 months (240 mg)
  • Brain metastases at baseline (n=17): Intracranial objective response rate 47% (8/17)
  • Safety: Dose reductions for treatment-related adverse events in 19% and 24%; discontinuation in 3% and 0%
  • Not reported: Overall survival, confidence intervals, length of follow-up, rates of grade 3 or higher adverse events, and intracranial response by dose

A structurally distinct EGFR subgroup with limited treatment options

The authors describe PACC mutations as a structurally distinct subgroup of EGFR mutations in NSCLC, and patients who carry them have limited treatment options. The paper pairs laboratory work on firmonertinib with first-line clinical data from the FURTHER study.

Firmonertinib is a brain-penetrant, mutant-selective EGFR inhibitor with a trifluoroethoxy side chain unique to the molecule. In EGFR PACC-mutant cell lines and xenograft models, it showed high anti-proliferative efficacy.

Responses in 68% of patients at 240 mg, against 43% at 160 mg

Both figures are confirmed objective response rates in first-line metastatic disease, measured in arms of 22 patients (240 mg) and 25 patients (160 mg). Patients were randomised between two doses of the same drug, so the study has no comparator arm of another EGFR inhibitor or of chemotherapy.

The median duration of response was 14.6 months in the 240 mg arm. In the 160 mg arm the median had not been reached when the data were reported, so the two arms cannot yet be compared on this endpoint.

Median progression-free survival of 16.0 months at the higher dose

Patients given 240 mg had a median progression-free survival of 16.0 months, 4.9 months longer than the 11.1 months observed with 160 mg. The abstract gives no hazard ratio or p value for the comparison between doses, and each arm holds fewer than 30 patients.

Intracranial responses in eight of 17 patients with brain metastases

Among patients with brain metastases at baseline, eight of 17 had an intracranial objective response, a rate of 47%. The investigators had described firmonertinib as brain-penetrant, and this is the clinical figure reported for that property in the trial.

Dose reductions in about a fifth to a quarter of patients, and few discontinuations

Treatment-related adverse events led to a dose reduction in 19% of patients at 160 mg and 24% at 240 mg. They led to discontinuation in 3% and 0% of patients, respectively. The higher dose, which produced the higher response rate and the longer median progression-free survival, did not lead more patients to stop treatment.

“Results support further study of first-line firmonertinib in patients with EGFR PACC-mutant NSCLC.”Le et al., Cancer Cell (2026)

Phase 1b evidence from 47 randomised PACC patients

The efficacy results come from 47 patients randomised between two doses in a phase 1b study. The authors present them as grounds for further study of first-line firmonertinib in this population.

The 240 mg arm had the higher response rate and the longer median progression-free survival, with no discontinuations for treatment-related adverse events. The abstract does not compare firmonertinib with any other treatment for PACC-mutant disease.

Sources

  1. Cancer Cell. Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and αC-helix compressing mutations (2026-10-01). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Xiuning Le, David Planchard and Maurice Pérol.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
Targeted Therapies

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

T. Newsom-DavisX. Le
Sep 26 2025
ILCS 2025
Targeted Therapies

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

S. Saw
Sep 26 2025
ILCS 2025
Targeted Therapies

Targeting EGFR and ALK in NSCLC

} 26 min

T. John
Sep 26 2025
ILCS 2025
Advanced NSCLC

Open Discussion on Patient Cases

} 22 min

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
Articles
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCBiomarkersADCs

Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC

J. SandsM. PérolN. Girard
Nov 12 2026
RESEARCH
BiomarkersResectable NSCLCTargeted Therapies

MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells

Z. Piotrowska
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 22 2026
RESEARCH
Advanced NSCLC

TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients

R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 16 2026
RESEARCH
Advanced NSCLC

Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study

L. Bubendorf
Oct 15 2026
NEWS
Resectable NSCLC

A papal diagnosis turns the world’s attention to its most diagnosed cancer

Oct 14 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue

N. Girard
Oct 08 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Amivantamab, lazertinib and bevacizumab gave a 33% response rate after osimertinib in AMAZE-lung

R. StahelM. PérolA. AddeoS. Peters
Oct 06 2026
RESEARCH
Advanced NSCLCImmunotherapies

Two-thirds of patients with PD-L1-high NSCLC received first-line immunotherapy alone in a real-world survey

D. Rodríguez-Abreu
Alfredo Addeo
Oct 05 2026
RESEARCH
Advanced NSCLCTargeted Therapies

A JCO review sets PACC mutations and exon 20 insertions apart from classical EGFR mutations in NSCLC

A. AddeoX. Le